LENSAR, Inc. is a commercial-stage medical device company. The Company is focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its product portfolio consists of the LENSAR Laser System and ALLY Adaptive Cataract Treatment System (ALLY System) and its associated consumable components. The system incorporates a range of technologies designed to assist the surgeon in obtaining visual outcomes. The consumable portion of the system consists of a disposable patient interface device kit. The ALLY System is designed to combine its femtosecond laser technology features with enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room or in-office surgical suite. Its system is used across surgeons, hospital outpatient surgical facilities and ambulatory surgery centers.
종목 코드 LNSR
회사 이름LENSAR Inc
상장일Sep 21, 2020
CEOMr. Nicholas T. (Nick) Curtis
직원 수140
유형Ordinary Share
회계 연도 종료Sep 21
주소2800 Discovery Drive
도시ORLANDO
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호32826
전화18885367271
웹사이트https://www.lensar.com/
종목 코드 LNSR
상장일Sep 21, 2020
CEOMr. Nicholas T. (Nick) Curtis
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음